Evonik is making a significant investment to strengthen manufacturing capabilities at its Lafayette (Tippecanoe), Indiana facility. Over the next five years, the company will invest US$100 million to modernize key equipment – including 100 m3 reactors and other critical systems – enhancing reliability, enabling greater automation, and improving ergonomics and efficiency. This investment is supported by local government and positions Evonik to meet the rapidly growing demand for U.S.-based drug substance CDMO services.
“Strengthening our U.S. drug substance business is a strategic necessity. With demand surging, Tippecanoe plays a pivotal role in creating a more resilient and globally balanced asset footprint,” said Guido Skudlarek, head of the Health Care business line at Evonik.
Evonik is balancing its global assets footprint across North America, Europe, and Asia, with a strategic emphasis on North America for its Drug Substance CDMO business. Evonik’s Tippecanoe site is a cornerstone of the company’s global CDMO network for small-molecule drug substances. The modernization at the Tippecanoe site is an investment into Next Generation Technologies which help preserve technology leadership and enhance energy-efficient processes. This investment into smart preservation CAPEX is a growth driver for the long run, strengthening cost leadership, while reducing greenhouse gas emissions, following Evonik’s strict CAPEX guiding principles.
Geopolitical uncertainties have underscored the importance of Western-based production for critical drug substances and delivery technologies. Moreover, modern therapeutic goals require increasingly complex molecules that are more challenging to manufacture. Evonik already supports complex synthesis but with rising molecular complexity, investment is needed to maintain and expand these capabilities.
API complexity continues to rise, and this investment empowers us to work with our customers on even more challenging molecules for critical indications such as cancer, metabolic and cardiovascular diseases.”
Daniel Fricker, Head of the Drug Substance Product Line, Evonik Health Care
Evonik’s Tippecanoe site is the company’s second-largest U.S. site and one of the world’s largest API facilities. It is home to the industry’s biggest high-potency API (HPAPI) operation with 170 m3 of dedicated capacity and advanced containment systems (OEL down to 0.1 μg/m3). The site also offers 860 m3 of reactor capacity for general APIs, 2,500 m3 for large-scale fermentation, and a technology portfolio spanning 10 advanced platforms. Acquired from Eli Lilly in 2010, Tippecanoe has evolved into a multi-customer CDMO serving complex drug substance projects.
